Corporate Profile
Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics.
Stock Quote
CRXM (Common)
ExchangeOTC BB (US Dollar)
Change (%)-0.00 (0.00%)
Data as of 12/05/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000CRXM
Recent News
09/12/16Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery DiseasePrinter Friendly Version
07/11/16Angionetics & A Huapont Life Sciences Affiliate Enter Agreement To Commercialize Generx® Angiogenic Gene Therapy Product Candidate For Ischemic Heart Disease In ChinaPrinter Friendly Version
07/11/16Angionetics & A Huapont Life Sciences (China) Affiliate Enter Into Equity Financing Agreement For Phase 3 Clinical Development Of Generx Gene Therapy For Ischemic Heart DiseasePrinter Friendly Version
Primary IR Contact
Shareholder Services
Corporate Communications/Investor Relations
11750 Sorrento Valley Road
San Diego, CA 92121

Phone: 858-436-1018

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.